<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874120</url>
  </required_header>
  <id_info>
    <org_study_id>18121</org_study_id>
    <secondary_id>CL2007-07</secondary_id>
    <secondary_id>P07529</secondary_id>
    <nct_id>NCT00874120</nct_id>
  </id_info>
  <brief_title>Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled double-blind, crossover design study; 116 subjects randomized
      on Day 1 to obtain 98 completed subjects. Study will be composed of a 7-day period of
      therapy with randomized active or placebo treatment with a subsequent 6-8 day washout
      period, followed by a second 7-day period of double-blind therapy with the other agent.
      Ambulatory blood pressure measurement will be performed beginning on Day 7 of each treatment
      period following administration of the study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).</measure>
    <time_frame>24 hours after final dose of each 7-day treatment period.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Five hour (hr) range around the Tmax was defined as approximately 2 hours before to approximately 2 hours after the Tmax, including Tmax. The parameters will be compared between active drug and placebo using analysis of variance (ANOVA). The 95% 2-sided Confidence Interval (CI) on the difference between treatments will also be presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Human Experimentation</condition>
  <arm_group>
    <arm_group_label>Phenylephrine HCl Extended-Release tablets 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine HCl Extended Release tablets 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg</intervention_name>
    <description>Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.</description>
    <arm_group_label>Phenylephrine HCl Extended-Release tablets 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken twice daily (12 hours apart) for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female volunteers must be 18 years or older, with a Body Mass Index
             (BMI) between 19-30 inclusive [BMI = weight (kilograms)/height (meters squared)].

          -  Clinical laboratory tests (complete blood count, blood chemistries, urinalysis),
             Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen, hepatitis
             C antibody must be within normal limits or clinically acceptable to the
             Investigator/Sponsor.

          -  Drug screen for drugs and alcohol with a high potential for abuse must be negative at
             screening.

          -  Subjects must be free of any clinically significant disease that requires a
             physician's care and/or would interfere with study evaluations, procedures or
             participation.

          -  Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks
             (14 days) prior to study participation and for two weeks (14 days) after the end of
             their study participation.

          -  Subjects must have normal or clinically acceptable physical exam and
             Electrocardiogram (ECG) intervals (PR, QRS, QT and QTc) on 12-lead ECG (recorded at
             25 millimeters/second [mm/s]).

          -  Subjects must have a mean after 5 minute of rest sitting systolic/diastolic office
             blood pressure ≤ 138/88 millimeters of mercury (mmHg).

          -  Subjects with controlled diabetes prior to entry must have a mean sitting after 5
             minute of rest systolic/diastolic office blood pressure ≤ 128/78 mmHg from
             non-dominated arm

          -  Females must have the urine or serum pregnancy test (Human Chorionic Gonadotropin)
             that is negative at Screening and Day 1 of Period 1.

          -  Female subjects of childbearing potential must be using medically acceptable birth
             control measures.

          -  Subjects must understand the dosing schedule.

          -  Subjects must be able to read and write in English.

        Exclusion Criteria:

          -  Subjects must not have any significant medical condition which, in the judgment of
             the Investigator, is a contraindication to the use of phenylephrine HCl, might
             interfere with the study or requires treatment expected to affect the blood pressure.
             These may include hyperthyroidism, hypothyroidism, uncontrolled diabetes mellitus,
             coronary heart disease, ischemic heart disease, elevated intraocular pressure,
             prostatic hypertrophy.

          -  Subjects who have a history of any clinically significant local or systemic
             infectious disease within four weeks prior to initial treatment administration.

          -  Subjects who have received an investigational drug within 30 days prior to study
             dosing.

          -  Subjects who are, appear to be, or are known, current or former drug addicts or
             alcoholics.

          -  Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.

          -  Subjects who are positive for HIV antibodies.

          -  Subjects who have a clinically significant history of food or drug allergy.

          -  Subjects who have a known allergy or intolerance to phenylephrine HCl.

          -  Females who are pregnant, nursing or unwilling to use/practice adequate contraception
             (hormonal, Intrauterine Device, barrier method, etc.).

          -  Subjects taking topical or oral decongestant products within 7 days of Visit 2.

          -  Subjects taking antihypertensive medication.

          -  Subjects taking monoamine oxidase inhibitors.

          -  Subjects taking tricyclic antidepressants (e.g. amitriptyline, nortriptyline,
             imipramine)

          -  Subjects taking antithyroid medication (e.g. propylthiouracil, methimazole, iodides).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 20, 2015</lastchanged_date>
  <firstreceived_date>April 1, 2009</firstreceived_date>
  <firstreceived_results_date>June 2, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenylephrine Followed by Placebo</title>
          <description>Phenylephrine hydrochloride (HCl) Extended Release tablets 30 mg twice daily for 7 days followed by a 6- to 8-day washout period followed by placebo twice daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Followed by Phenylephrine</title>
          <description>Placebo twice daily for 7 days followed by a 6- to 8-day washout period followed by Phenylephrine HCl Extended Release tablets 30 mg twice daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive drug test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash-out Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenylephrine Followed by Placebo</title>
          <description>Phenylephrine hydrochloride (HCl) Extended Release tablets 30 mg twice daily for 7 days followed by a 6- to 8-day washout period followed by placebo twice daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by Phenylephrine</title>
          <description>Placebo twice daily for 7 days followed by a 6- to 8-day washout period followed by Phenylephrine HCl Extended Release tablets 30 mg twice daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="116"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.4" spread="10.14"/>
                <measurement group_id="B2" value="29.0" spread="10.99"/>
                <measurement group_id="B3" value="29.2" spread="10.53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).</title>
        <description>Five hour (hr) range around the Tmax was defined as approximately 2 hours before to approximately 2 hours after the Tmax, including Tmax. The parameters will be compared between active drug and placebo using analysis of variance (ANOVA). The 95% 2-sided Confidence Interval (CI) on the difference between treatments will also be presented.</description>
        <time_frame>24 hours after final dose of each 7-day treatment period.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The per-protocol population included 100 participants who completed both treatment periods and have 24-hour Ambulatory Blood Pressure Monitoring (ABPM) data for SBP measurements for each study drug, 46 participants who received phenylephrine followed by placebo and 54 participants who received placebo followed by phenylephrine.</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine HCl Extended Release tablets 30 mg twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).</title>
            <description>Five hour (hr) range around the Tmax was defined as approximately 2 hours before to approximately 2 hours after the Tmax, including Tmax. The parameters will be compared between active drug and placebo using analysis of variance (ANOVA). The 95% 2-sided Confidence Interval (CI) on the difference between treatments will also be presented.</description>
            <units>mmHg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="118.3" spread="9.24"/>
                  <measurement group_id="O2" value="118.6" spread="9.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5480</p_value>
            <p_value_desc>P-value is based on an ANOVA model including sequence, subject within sequence, period and treatment as factors.</p_value_desc>
            <method>ANOVA</method>
            <param_type>residual error term from the ANOVA</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Intent-to-treat population. Participants who received at least one dose of study medication were included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phenylephrine</title>
          <description>Phenylephrine HCL Extended Release tablets 30 mg twice daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo twice daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor reserves all publication and presentation rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
